FTRE vs IQV: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. FTRE and IQV share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined FTRE and IQV exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Fortrea Holdings is a global contract research organization (CRO) that runs clinical trials on behalf of pharmaceutical, biotech and medical device companies. It was separated from Labcorp in July 2023 and largely traces back to Covance, which Labcorp bought in 2015. Fortrea operates in roughly 90 countries and has three main pieces of business. Clinical pharmacology covers early-stage Phase I studies run in its own clinical units, where healthy volunteers or patients receive a drug for the first time. Full-service clinical development means managing Phase II to IV trials end to end, from site selection and patient recruitment through data management and regulatory submission. Functional service provision, or FSP, supplies dedicated staff who work inside a sponsor's own trial operations. Revenue comes from multi-year contracts, which is why backlog (about ~$7.8 billion at June 30, 2026, or nearly three years of revenue) is the number analysts watch most closely.

Full FTRE guide

IQVIA Holdings is a healthcare-focused data, analytics, and clinical-research company formed in 2016 from the merger of Quintiles (a large CRO) and IMS Health (a pharmaceutical-data provider). It operates in three segments: Technology & Analytics Solutions, which sells prescription and market data, real-world evidence, and commercial software to drug and device makers; Research & Development Solutions, its clinical research organization arm that designs and runs clinical trials on behalf of pharma and biotech sponsors; and Contract Sales & Medical Solutions. IQVIA makes money from long-duration trial contracts, recurring data and software subscriptions, and consulting, serving essentially all of the top 20 global pharmaceutical companies.

Full IQV guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• FTRE drivers: Bookings recovery feeding the backlog; Cost structure after the Labcorp separation.
• IQV drivers: Record backlog and bookings momentum; Proprietary data and analytics moat.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Revenue is still declining year over year, so the recovery case rests on bookings converting to growth rather than on results already delivered. For IQV, iQVIA's demand is tied to pharma and biotech R&D budgets, which are cyclical: biopharma funding fell about 20 percent in 2025 to roughly $82 billion as IPOs hit a decade low, and prolonged funding weakness can slow trial starts, RFP flow, and bookings.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick FTRE if you believe its drivers more; IQV if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the FTRE and IQV guides.

FTRE. On GAAP numbers Fortrea is still loss-making (a ~$13 million net loss in Q2 2026 and roughly ~$85 million over the trailing twelve months), so the stock is usually valued on adjusted earnings, where the forward P/E is about ~24x, and on enterprise value. At roughly ~$3.1 billion, enterprise value is about ~14 to ~15x the midpoint of 2026 adjusted EBITDA guidance and a little over 1x sales. That multiple is not cheap for a company whose revenue is shrinking, which means the current price leans on margin expansion and a return to growth in 2027. For comparison, the stock traded near ~$850 to ~$880 million of market cap in late March and early April 2026, so most of the rerating has come from the Q2 beat and guidance raise. Post-earnings analyst targets in July 2026 ranged from roughly ~$20 (Deutsche Bank) to ~$26 (Truist), and the stock now sits near the upper half of that range. Fortrea's next quarterly report, for Q3 2026, is the next test of whether bookings are turning into revenue.

IQV. At about $268 on October 16, 2026, IQVIA traded near 19 times forward earnings and about 33 times trailing GAAP earnings, the gap reflecting amortization and other items excluded from adjusted EPS. Analysts expect adjusted EPS of about $12.96 for 2026 and $14.42 for 2027 on revenue of about $17.4 billion and $18.5 billion, and the average target among 19 analysts tracked by Yahoo was about $300. Third-quarter results on October 27, 2026 (consensus about $3.27 a share on $4.37 billion of revenue) will show whether bookings and backlog support those numbers.

Headline figures (approximate, October 2026): FTRE shows revenue (ttm) ~$2.68 billion, 2026 revenue guidance ~$2.62 to ~$2.69 billion, 2026 adjusted ebitda guidance ~$205 to ~$220 million, market cap ~$2.2 billion (share price ~$22.75); IQV shows revenue (ttm) ~$17.0 billion, revenue growth (q2 2026, yoy) ~8.7%, margins (ttm) Gross ~33%; operating ~13%; net ~8%, adjusted eps (q2 2026) $3.15 vs $3.03 estimate.

FTRE and IQV are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined FTRE and IQV exposure against your real portfolio. It is not an investment adviser.